JP2012121846A - 悪液質改善剤 - Google Patents
悪液質改善剤 Download PDFInfo
- Publication number
- JP2012121846A JP2012121846A JP2010274339A JP2010274339A JP2012121846A JP 2012121846 A JP2012121846 A JP 2012121846A JP 2010274339 A JP2010274339 A JP 2010274339A JP 2010274339 A JP2010274339 A JP 2010274339A JP 2012121846 A JP2012121846 A JP 2012121846A
- Authority
- JP
- Japan
- Prior art keywords
- cachexia
- cancer
- ghrelin
- sojutsu
- rikkunshito
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010006895 Cachexia Diseases 0.000 title claims abstract description 54
- 230000006872 improvement Effects 0.000 title claims abstract description 6
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 14
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 4
- 102000000393 Ghrelin Receptors Human genes 0.000 claims description 12
- 108010016122 Ghrelin Receptors Proteins 0.000 claims description 12
- 239000012190 activator Substances 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 abstract description 14
- 206010028980 Neoplasm Diseases 0.000 abstract description 12
- 241000132011 Atractylodes lancea Species 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 21
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 18
- 102100033367 Appetite-regulating hormone Human genes 0.000 description 17
- 101800001586 Ghrelin Proteins 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000012153 distilled water Substances 0.000 description 14
- 230000000694 effects Effects 0.000 description 10
- 230000027455 binding Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 230000008602 contraction Effects 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 235000019515 salmon Nutrition 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 208000016261 weight loss Diseases 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- 241000972773 Aulopiformes Species 0.000 description 4
- 241000202807 Glycyrrhiza Species 0.000 description 4
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 4
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 4
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 4
- 230000005176 gastrointestinal motility Effects 0.000 description 4
- 229940010454 licorice Drugs 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 208000002720 Malnutrition Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000001071 malnutrition Effects 0.000 description 3
- 235000000824 malnutrition Nutrition 0.000 description 3
- 208000015380 nutritional deficiency disease Diseases 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108010074051 C-Reactive Protein Proteins 0.000 description 2
- 102100032752 C-reactive protein Human genes 0.000 description 2
- 244000000626 Daucus carota Species 0.000 description 2
- 235000002767 Daucus carota Nutrition 0.000 description 2
- 235000011511 Diospyros Nutrition 0.000 description 2
- 244000236655 Diospyros kaki Species 0.000 description 2
- 235000006484 Paeonia officinalis Nutrition 0.000 description 2
- 244000170916 Paeonia officinalis Species 0.000 description 2
- 244000131316 Panax pseudoginseng Species 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 244000273928 Zingiber officinale Species 0.000 description 2
- 235000006886 Zingiber officinale Nutrition 0.000 description 2
- 244000126002 Ziziphus vulgaris Species 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 235000008397 ginger Nutrition 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- ZTVSGQPHMUYCRS-SWLSCSKDSA-N (4as,8as)-3,8a-dimethyl-5-methylidene-4a,6,7,8-tetrahydro-4h-benzo[f][1]benzofuran-2-one Chemical compound C=C([C@@H]1C2)CCC[C@]1(C)C=C1C2=C(C)C(=O)O1 ZTVSGQPHMUYCRS-SWLSCSKDSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101710111255 Appetite-regulating hormone Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- OQYBLUDOOFOBPO-UHFFFAOYSA-N Asterolide Natural products C1C2C(=C)CCCC2(C)CC2C1=C(C)C(=O)O2 OQYBLUDOOFOBPO-UHFFFAOYSA-N 0.000 description 1
- 241000984231 Atractylodes chinensis Species 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 244000274847 Betula papyrifera Species 0.000 description 1
- 235000009113 Betula papyrifera Nutrition 0.000 description 1
- 235000009109 Betula pendula Nutrition 0.000 description 1
- 235000010928 Betula populifolia Nutrition 0.000 description 1
- 235000002992 Betula pubescens Nutrition 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000723298 Dicentrarchus labrax Species 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- 102100039256 Growth hormone secretagogue receptor type 1 Human genes 0.000 description 1
- 101710202385 Growth hormone secretagogue receptor type 1 Proteins 0.000 description 1
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 1
- 208000003623 Hypoalbuminemia Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000008848 allosteric regulation Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003324 growth hormone secretagogue Substances 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000009430 psychological distress Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000002484 serotonin 2C antagonist Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
- JLQFVGYYVXALAG-CFEVTAHFSA-N yasmin 28 Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 JLQFVGYYVXALAG-CFEVTAHFSA-N 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
グレリンの受容体結合活性の増強:
125Iでラベルしたヒトグレリンを0.03nMの濃度となるようにHEPESバッファー*1で溶解し、グレリン溶液を調製した。このグレリン溶液と、ツムラ六君子湯エキス顆粒(医療用)(2〜200μg/mL)およびその成分(1〜100μmol/L)の1%ジメチルスルホキシド(DMSO)溶解液の各々を、ヒト遺伝子組み換えグレリン受容体(Growth hormone secretagogue receptor;GHS−R)を発現させたCHO(Chinese hamster ovary)−K1細胞と25℃で60分間反応させた。
25mM 4−(2−ヒドロキシエチル)−1−ピペラジンエタンスルホン酸
(HEPES;pH 7.4)、5mM MgCl2、1mM CaCl2、
0.4% ウシ血清アルブミン(BSA)
ガン悪液質ラットにおける六君子湯およびソウジュツ由来成分の延命作用:
ウイスター(Wistar)系雄性ラット(6週齢)に、肝癌細胞AH−130
(108cells/rat)を腹腔内移植し、移植当日よりツムラ六君子湯エキス顆粒(医療用)(125、250、500mg/kg)を1日2回、連日経口投与した。その結果、六君子湯はラットの生存日数を延長させた(図4)。
ガン悪液質ラットの消化管運動、体重、筋肉量に対するソウジュツを含有する六君子湯の作用:
(1)消化管運動を測定するために、ウイスター(Wistar)系雄性ラット(8週齢)の胃前庭部および十二指腸の漿膜面にストレインゲージ・フォース・トランスデューサーを縫着した。3日後に癌細胞AH−130を108cell/ratで腹腔内移植し、その5日目に絶食下で消化管運動を測定した。この結果、ガン悪液質ラットの空腹期収縮(phase III様収縮)は、正常ラットと比較して低下していた。
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010274339A JP5692785B2 (ja) | 2010-12-09 | 2010-12-09 | 悪液質改善剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010274339A JP5692785B2 (ja) | 2010-12-09 | 2010-12-09 | 悪液質改善剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012121846A true JP2012121846A (ja) | 2012-06-28 |
JP5692785B2 JP5692785B2 (ja) | 2015-04-01 |
Family
ID=46503696
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010274339A Active JP5692785B2 (ja) | 2010-12-09 | 2010-12-09 | 悪液質改善剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5692785B2 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019168388A1 (ko) * | 2018-02-28 | 2019-09-06 | 중앙대학교 산학협력단 | 악액질 및 근손실 예방, 개선 또는 치료용 조성물 |
JP2019202969A (ja) * | 2018-05-24 | 2019-11-28 | 公立大学法人大阪 | 骨格筋強化剤 |
JP2021107358A (ja) * | 2019-12-27 | 2021-07-29 | クラシエ製薬株式会社 | グレリン受容体の活性化剤 |
-
2010
- 2010-12-09 JP JP2010274339A patent/JP5692785B2/ja active Active
Non-Patent Citations (3)
Title |
---|
JPN6014019091; '六君子湯によるグレリン分泌亢進メカニズム' 漢方医学 Vol.34,No.3, Page.254-255 * |
JPN6014019092; 乾明夫: 'さまざまな疾患で注目される悪液質' 漢方医学 Vol.34 No.1 Page.74-75, 201001, Page.74-75 * |
JPN6014019093; 武田宏司 他: '機能性ディスペプシアおよび食欲不振に対する漢方治療' 日本消化器病学会雑誌 Vol.107,No.10, 201010, Page.1586-1591 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019168388A1 (ko) * | 2018-02-28 | 2019-09-06 | 중앙대학교 산학협력단 | 악액질 및 근손실 예방, 개선 또는 치료용 조성물 |
US11684650B2 (en) | 2018-02-28 | 2023-06-27 | Chung-Ang University Industry Academic Cooperation Foundation | Composition for preventing, alleviating, or treating cachexia and muscle loss |
JP2019202969A (ja) * | 2018-05-24 | 2019-11-28 | 公立大学法人大阪 | 骨格筋強化剤 |
JP7193073B2 (ja) | 2018-05-24 | 2022-12-20 | 公立大学法人大阪 | 骨格筋強化剤 |
JP2021107358A (ja) * | 2019-12-27 | 2021-07-29 | クラシエ製薬株式会社 | グレリン受容体の活性化剤 |
JP7430442B2 (ja) | 2019-12-27 | 2024-02-13 | クラシエ株式会社 | グレリン受容体の活性化剤 |
Also Published As
Publication number | Publication date |
---|---|
JP5692785B2 (ja) | 2015-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Feldman et al. | Histamine2-receptor antagonists: standard therapy for acid-peptic diseases | |
TW410156B (en) | Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y with raloxifene and the derivatives thereof | |
BR112021015129A2 (pt) | Método para tratar um paciente que sofre de hipercortisolemia e um sintoma ou comorbidade da mesma | |
CN104010636A (zh) | 三环化合物、包含它们的组合物及其用途 | |
JP5692785B2 (ja) | 悪液質改善剤 | |
ES2864153T3 (es) | Nueva forma de cristal de dapagliflozina y método de preparación y uso de la misma | |
PT1446112E (pt) | Utilização de glutamato, derivados ou metabolitos de glutamato, análogos de glutamato ou misturas dos mesmos para o fabrico de uma composição para o tratamento da osteoporose | |
CN118401254A (zh) | Kras g12d抑制剂与shp-2抑制剂的组合疗法 | |
KR20200055116A (ko) | Pi3 키나아제 억제제 및 면역관문 억제제를 포함하는 암의 예방 또는 치료용 약학적 조성물 | |
JP5388602B2 (ja) | 抗肥満用医薬組成物 | |
BR112019010564A2 (pt) | composição e uso de uma composição | |
JP7366545B2 (ja) | 食欲不振改善用組成物 | |
CN104000877A (zh) | 一种降糖组合物及其应用 | |
WO2020067832A1 (ko) | 티아민 유도체를 포함하는 고코르티솔증 예방 또는 치료용 조성물 | |
Wolmarans | Maintaining euthyroidism: fundamentals of thyroid hormone physiology, iodine metabolism and hypothyroidism | |
Singh et al. | Evaluation of anti-anxiety activity of Mucuna pruriens | |
EP3060214A2 (en) | Cns stimulant and opioid receptor antagonist combination as a non- addictive, non-aversive and synergistic anti-obesity treatment | |
WO2013138600A1 (en) | Radioprotector compounds | |
KR20200055117A (ko) | Pi3 키나아제 억제제 및 세포독성 항암제를 포함하는 암의 예방 또는 치료용 약학적 조성물 | |
WO2020030648A1 (en) | Tissue transglutaminase modulators for medicinal use | |
JP2016034930A (ja) | 血糖値低減剤 | |
KR101737051B1 (ko) | 당뇨병 치료용 약학적 조성물 | |
US20230255955A1 (en) | Ameliorating agent or prophylactic agent for muscle weakness symptom in disease or syndrome associated with metabolic disorder | |
JP2014532077A (ja) | 抗糖尿病アミノステロイド誘導体 | |
US9775828B2 (en) | Pharmaceutical composition with increased solubility by using saccharin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130412 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130412 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140520 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140627 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20140627 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140812 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141014 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20141021 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150106 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150129 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5692785 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |